NO963347L - Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet - Google Patents

Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet

Info

Publication number
NO963347L
NO963347L NO963347A NO963347A NO963347L NO 963347 L NO963347 L NO 963347L NO 963347 A NO963347 A NO 963347A NO 963347 A NO963347 A NO 963347A NO 963347 L NO963347 L NO 963347L
Authority
NO
Norway
Prior art keywords
individuals suffering
identifying individuals
cellular abnormality
abnormality
cellular
Prior art date
Application number
NO963347A
Other languages
English (en)
Norwegian (no)
Other versions
NO963347D0 (no
Inventor
Pierre Van Der Bruggen
Jean-Pierre Szikora
Pierre Coulie
Claude Wildman
Pascale Boel
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/195,186 external-priority patent/US5558995A/en
Priority claimed from US08/196,630 external-priority patent/US5683886A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO963347D0 publication Critical patent/NO963347D0/no
Publication of NO963347L publication Critical patent/NO963347L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
NO963347A 1994-02-14 1996-08-12 Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet NO963347L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/195,186 US5558995A (en) 1993-01-22 1994-02-14 Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US08/196,630 US5683886A (en) 1993-06-17 1994-02-15 Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof
US08/292,492 US6328971B1 (en) 1993-01-22 1994-08-18 MAGE-1 derived nona peptides, and compositions thereof
PCT/US1995/001446 WO1995021630A1 (en) 1994-02-14 1995-01-26 Methods for identifying individuals suffering from a cellular abnormality

Publications (2)

Publication Number Publication Date
NO963347D0 NO963347D0 (no) 1996-08-12
NO963347L true NO963347L (no) 1996-08-14

Family

ID=27393408

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963347A NO963347L (no) 1994-02-14 1996-08-12 Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet

Country Status (14)

Country Link
US (1) US6328971B1 (fi)
EP (1) EP0789591B1 (fi)
JP (1) JP2002502224A (fi)
AT (1) ATE237685T1 (fi)
AU (1) AU697246B2 (fi)
CA (1) CA2182969A1 (fi)
DE (1) DE69530410T2 (fi)
DK (1) DK0789591T3 (fi)
ES (1) ES2197196T3 (fi)
FI (1) FI963170A0 (fi)
NO (1) NO963347L (fi)
NZ (1) NZ282938A (fi)
PT (1) PT789591E (fi)
WO (1) WO1995021630A1 (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5877017A (en) * 1993-06-17 1999-03-02 Ludwig Institute For Cancer Research Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
EP1117679B9 (en) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US6407063B1 (en) * 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2002044723A2 (en) * 2000-11-28 2002-06-06 Eileen Louise Rice Mcfarland Method for diagnosing a predisposition of psychosis in a progeny

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066783A (en) * 1986-05-20 1991-11-19 Cohen Eric A Antiviral peptides and means for treating herpes infections
ES2236682T5 (es) * 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
CA2154468A1 (en) * 1993-01-22 1994-08-04 Pierre Van Der Bruggen Method for identifying and treating individuals bearing cancer cells that express hla-c-clone 10/mage-1
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
WO1996010413A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor

Also Published As

Publication number Publication date
FI963170A (fi) 1996-08-13
CA2182969A1 (en) 1995-08-17
PT789591E (pt) 2003-08-29
JP2002502224A (ja) 2002-01-22
NZ282938A (en) 2000-01-28
EP0789591B1 (en) 2003-04-16
US6328971B1 (en) 2001-12-11
DE69530410D1 (de) 2003-05-22
FI963170A0 (fi) 1996-08-13
DE69530410T2 (de) 2004-03-25
AU697246B2 (en) 1998-10-01
DK0789591T3 (da) 2003-05-19
ES2197196T3 (es) 2004-01-01
AU2089995A (en) 1995-08-29
NO963347D0 (no) 1996-08-12
EP0789591A4 (en) 1998-07-01
EP0789591A1 (en) 1997-08-20
ATE237685T1 (de) 2003-05-15
WO1995021630A1 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
ATE214924T1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
DK0749582T3 (da) Fremgangsmåde til diagnosticering af præeklampsi
DE69526216D1 (de) Antifungaleverfahren und mitteln
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
NO952385D0 (no) Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen
NO963347L (no) Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
DE69608683D1 (de) Analytisches und therapeutisches mittel
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
TR199802118A3 (tr) Egzoz gazlarinin aritilmasi için yöntem ve düzenleme.
DK0786083T3 (da) Fremgangsmåde til diagnostisk bedømmelse af forløbskontrol samt lægemiddel til terapi af choktilstande hos mennesker
MX9606031A (es) Inhibidores de cetona perfluoroalquilica de elastasa y procesos para fabricarlos.
NO984190L (no) FremgangsmÕte for behandling av insomnia
UA33267A (uk) Спосіб діагностики гострого отруєння алкоголем
UA6640A (uk) Спосіб прогнозування загострення супутнього захворювання при активізації основної патології

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application